FINANCIAL FEASIBILITY OF BUSINESS ON HEALTH STARTUP: A CASE STUDY OF SEMUDAH HEALTH
According to INFODATIN in 2020 there are around 10.7 million Indonesians who suffer from diabetes mellitus. One of the factors that causes the high number of people with diabetes in Indonesia is the lack of knowledge of the Indonesian people about diabetes mellitus and there are still many Indone...
Saved in:
| Main Author: | |
|---|---|
| Format: | Final Project |
| Language: | Indonesia |
| Online Access: | https://digilib.itb.ac.id/gdl/view/67079 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | According to INFODATIN in 2020 there are around 10.7 million Indonesians who suffer
from diabetes mellitus. One of the factors that causes the high number of people with
diabetes in Indonesia is the lack of knowledge of the Indonesian people about diabetes
mellitus and there are still many Indonesians who are reluctant to check blood sugar levels
regularly. They argue that they feel uncomfortable when checking blood sugar levels
because they have to hurt themselves to be able to take blood samples. SEMUDAH
HEALTH is a start-up company that is interested in dealing with this problem, namely by
making a non-invasive blood sugar level checker using near infrared spectroscopy
technology, but so far it has not yet conducted a financial feasibility study. The purpose
of this research is to conduct a financial feasibility study for the development of the
SEMUDAH HEALTH company. This study uses a quantitative approach with company
data as primary data and similar company data as secondary data. Financial feasibility
will be analyzed using the payback period Net Present Value (NPV) method, and the
Internal Rate of Return (IRR) then the risk will be assessed using scenario analysis. The
results of the study show that SEMUDAH HEALTH is financially feasible with a payback
period of 2.55 years, with NPV of Rp. 1,147,577,056, and an IRR of 48.73%, which
percentage figure is greater than the Weighted Average Cost of Capital (WACC) of 4.24%.
Keywords:
Financial Feasibility, Diabetes Mellitus, Capital Budgeting |
|---|